X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Glenmark Pharma with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ACTAVIS (US) - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   ACTAVIS
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
ACTAVIS
Dec-14
GLENMARK PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs99319,145-   
Low Rs72911,678-   
Sales per share (Unadj.) Rs325.53,447.5-  
Earnings per share (Unadj.) Rs39.3-430.2-  
Cash flow per share (Unadj.) Rs48.7316.3-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs159.27,477.5-  
Shares outstanding (eoy) m282.17265.90-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.64.5 59.2%   
Avg P/E ratio x21.9-35.8 -61.2%  
P/CF ratio (eoy) x17.748.7 36.3%  
Price / Book Value ratio x5.42.1 262.4%  
Dividend payout %5.10-   
Avg Mkt Cap Rs m242,9914,097,925 5.9%   
No. of employees `00013.021.6 60.0%   
Total wages/salary Rs m16,4080-   
Avg. sales/employee Rs Th7,083.942,439.4 16.7%   
Avg. wages/employee Rs Th1,265.40-   
Avg. net profit/employee Rs Th855.1-5,296.0 -16.1%   
INCOME DATA
Net Sales Rs m91,857916,691 10.0%  
Other income Rs m374-2,288 -16.3%   
Total revenues Rs m92,230914,403 10.1%   
Gross profit Rs m20,367117,762 17.3%  
Depreciation Rs m2,644198,497 1.3%   
Interest Rs m2,37328,914 8.2%   
Profit before tax Rs m15,724-111,937 -14.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-810-8,211 9.9%   
Tax Rs m3,827-5,755 -66.5%   
Profit after tax Rs m11,088-114,393 -9.7%  
Gross profit margin %22.212.8 172.6%  
Effective tax rate %24.35.1 473.4%   
Net profit margin %12.1-12.5 -96.7%  
BALANCE SHEET DATA
Current assets Rs m68,746482,979 14.2%   
Current liabilities Rs m27,027352,233 7.7%   
Net working cap to sales %45.414.3 318.4%  
Current ratio x2.51.4 185.5%  
Inventory Days Days8558 146.5%  
Debtors Days Days9666 144.1%  
Net fixed assets Rs m24,132111,937 21.6%   
Share capital Rs m2820-   
"Free" reserves Rs m44,6430-   
Net worth Rs m44,9251,988,270 2.3%   
Long term debt Rs m45,3631,041,892 4.4%   
Total assets Rs m117,6393,643,844 3.2%  
Interest coverage x7.6-2.9 -265.6%   
Debt to equity ratio x1.00.5 192.7%  
Sales to assets ratio x0.80.3 310.4%   
Return on assets %11.4-2.3 -487.8%  
Return on equity %24.7-5.8 -429.0%  
Return on capital %19.1-3.0 -635.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m48,0680-   
CASH FLOW
From Operations Rs m6,574157,414 4.2%  
From Investments Rs m-7,124-376,909 1.9%  
From Financial Activity Rs m5,432211,768 2.6%  
Net Cashflow Rs m1,992-7,727 -25.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 70.18 Rs / USD

Compare GLENMARK PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare GLENMARK PHARMA With: PANACEA BIOTECH  IPCA LABS  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  SHASUN PHARMA  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views On News

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6% (Quarterly Result Update)

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Aug 17, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - JUBILANT LIFE SCIENCES COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS